METHODS: A multistage modified Delphi process was undertaken with a Clinical Advisory Group of multidisciplinary lung cancer specialists, with patient representation, to update and prioritise potential indicators of lung cancer care derived from a targeted review of published literature and reports from national and international lung cancer quality registries. Quality indicators were piloted and evaluated with multidisciplinary teams in a retrospective observational cohort study using clinical audit data from the Embedding Research (and Evidence) in Cancer Healthcare Program, a prospective clinical cohort of over 2000 patients with lung cancer diagnosed from May 2016 to October 2021.
METHODS: Six tertiary specialist cancer centres in metropolitan and regional New South Wales, Australia.
RESULTS: From an initial 37 potential quality indicators, a final set of 10 indicators spanning diagnostic, treatment, quality of life and survival domains was agreed.
CONCLUSIONS: These indicators build on and update previously available measures of lung cancer care and outcomes in use by national and international lung cancer clinical quality registries which, to our knowledge, have not been recently updated to reflect the changing lung cancer treatment paradigm.
方法:由多学科肺癌专家组成的临床咨询小组进行了多阶段的改良Delphi过程。有病人代表,更新和优先考虑肺癌治疗的潜在指标,这些指标来自对国家和国际肺癌质量登记处已发表的文献和报告的有针对性的审查。质量指标在回顾性观察队列研究中,使用来自癌症医疗保健计划中的嵌入研究(和证据)的临床审核数据,与多学科团队一起进行了试点和评估。对2016年5月至2021年10月诊断的2000多名肺癌患者进行前瞻性临床队列研究.
方法:新南威尔士州大都市和地区的六个三级癌症专科中心,澳大利亚。
结果:从最初的37项潜在质量指标来看,最后一组涵盖诊断的10个指标,治疗,生活质量和生存领域达成一致。
结论:这些指标建立并更新了国家和国际肺癌临床质量登记处以前可用的肺癌护理和结果衡量标准,根据我们的知识,最近没有更新以反映不断变化的肺癌治疗模式。